Regorafenib in combination with temozolomide with or without radiotherapy in patients with newly diagnosed MGMT-Methylated, IDH wild-type glioblastoma. A phase I dose-finding study (REGOMA-2).

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514424-16-00

Acronym

REGOMA-2

Enrollment

Registered

2025-01-27

Start date

2022-07-04

Completion date

2025-12-22

Last updated

2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IDH wild-type glioblastoma, MGMT-Methylated

None listed

Sex/Gender

All

Age

18 Years to No maximum

Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026